In this context, it was reported that upregulation of the WNT3 ligand in HER2-positive (HER2+) BC cells resistant to trastuzumab, the gold standard regimen for HER2+ BC patients, activates the Wnt/β-catenin pathway and promotes the EMT-like transition. Here, WNT3 is linked to breast cancer.